G. Forte

发表

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality

M. Bartolini, G. Giannelli, L. Ottini, 2020, iScience.

Characterization of a rare variant (c.2635-2A>G) of the MSH2 gene in a family with Lynch syndrome

A. Di Carlo, M. Caruso, A. Valentini, 2018, The International journal of biological markers.

CSNK1A1 expression modifies TP53 effects on survival of colon cancer patients

H. Morreau, J. Oosting, W. Corver, 2012 .

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors

M. Cutrone, R. Tenconi, L. Chessa, 2015, PloS one.

c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer

G. Giannelli, A. Valentini, C. Simone, 2022, Cancers.

Short Linear Motifs in Colorectal Cancer Interactome and Tumorigenesis

C. Simone, C. Fasano, G. Forte, 2022, Cells.

A rare MSH2 mutation causes defective binding to hMSH6, normal hMSH2 staining, and loss of hMSH6 at advanced cancer stage.

G. Ingravallo, C. Simone, A. Stella, 2014, Human pathology.

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality

M. Bartolini, G. Giannelli, L. Ottini, 2020, iScience.

Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients

D. Piscitelli, A. Stella, N. Resta, 2012, The International journal of biological markers.

Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy

V. Celestini, Domenico de Rasmo, A. Signorile, 2018, Cell Death & Disease.

Pharmacological targeting of the novel β-catenin chromatin-associated kinase p38α in colorectal cancer stem cell tumorspheres and organoids

G. Stassi, G. Giannelli, G. Ingravallo, 2021, Cell Death & Disease.

FOXO3 on the Road to Longevity: Lessons From SNPs and Chromatin Hubs

C. Simone, V. Disciglio, P. Sanese, 2019, Computational and structural biotechnology journal.

The longevity SNP rs2802292 uncovered: HSF1 activates stress-dependent expression of FOXO3 through an intronic enhancer

C. Simone, N. Resta, F. Susca, 2018, Nucleic acids research.

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

C. Simone, S. Di Tommaso, A. Selicorni, 2018, neurogenetics.

Identifying novel SMYD3 interactors on the trail of cancer hallmarks

C. Simone, P. Sanese, C. Fasano, 2022, Computational and structural biotechnology journal.

Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38

P. Ditonno, M. Battaglia, E. Maiorano, 2015, Autophagy.

Identification and Somatic Characterization of the Germline PTEN Promoter Variant rs34149102 in a Family with Gastrointestinal and Breast Tumors

A. Valentini, C. Simone, V. Disciglio, 2022, Genes.

APC Splicing Mutations Leading to In-Frame Exon 12 or Exon 13 Skipping Are Rare Events in FAP Pathogenesis and Define the Clinical Outcome

C. Simone, V. Disciglio, P. Sanese, 2021, Genes.

APC Splicing Mutations Leading to In-Frame Exon Skipping are Rare Events in FAP Pathogenesis and Define the Clinical Outcome

C. Simone, V. Disciglio, P. Sanese, 2021 .

Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation

A. Andriulli, A. Piepoli, A. Panza, 2011, Familial Cancer.

Characterization of the rs2802292 SNP identifies FOXO3A as a modifier locus predicting cancer risk in patients with PJS and PHTS hamartomatous polyposis syndromes

M. Genuardi, V. Celestini, C. Simone, 2014, BMC Cancer.

Gastric polyposis and desmoid tumours as a new familial adenomatous polyposis clinical variant associated with APC mutation at the extreme 3′-end

C. Simone, V. Disciglio, A. Stella, 2019, Journal of Medical Genetics.

Unopposed estrogens: current and future perspectives.

V. Unfer, G. Forte, G. Porcaro, 2022, European review for medical and pharmacological sciences.

401 Loss of LKB1/STK11 expression is an early event in prostate cancer development and predicts therapeutic response to p38α inhibitor

P. Ditonno, M. Battaglia, C. Simone, 2015 .

Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy

V. Celestini, Domenico de Rasmo, A. Signorile, 2018, Cell Death & Disease.

The longevity SNP rs2802292 uncovered: HSF1 activates stress-dependent expression of FOXO3 through an intronic enhancer

C. Simone, N. Resta, F. Susca, 2018, Nucleic acids research.

Tumor Testing and Genetic Analysis to Identify Lynch Syndrome Patients in an Italian Colorectal Cancer Cohort

A. Valentini, A. L. Buonadonna, P. Sanese, 2023, Cancers.

SMYD3 Modulates AMPK-mTOR Signaling Balance in Cancer Cell Response to DNA Damage

G. Varchi, P. Sanese, C. Fasano, 2023, Cells.

Classic Galactosemia: Clinical and Computational Characterization of a Novel GALT Missense Variant (p.A303D) and a Literature Review

A. L. Buonadonna, P. Sanese, C. Fasano, 2023, International Journal of Molecular Sciences.

Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review

P. Sanese, C. Fasano, G. Forte, 2023, Cancers.

The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance

M. Naldi, G. Varchi, C. Ferroni, 2024, Journal of experimental & clinical cancer research : CR.

In Silico Deciphering of the Potential Impact of Variants of Uncertain Significance in Hereditary Colorectal Cancer Syndromes

P. Sanese, C. Fasano, G. Forte, 2024, Cells.

Methyltransferases in cancer drug resistance: Unlocking the potential of targeting SMYD3 to sensitize cancer cells.

P. Sanese, C. Fasano, G. Forte, 2024, Biochimica et biophysica acta. Reviews on cancer.

The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging ‘nonmutational epigenetic reprogramming’ cancer hallmark

P. Sanese, C. Fasano, G. Forte, 2023, Computational and structural biotechnology journal.

SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer

G. Varchi, P. Sanese, C. Fasano, 2023, Cells.